ПРИНЦИПЫ ВЫБОРА АНТИХЕЛИКОБАКТЕРНОЙ ТЕРАПИИ 1-й ЛИНИИ

Скачать статью в PDF
Номер журнала: 
9
Год издания: 
2015

А. Свистунов (1), доктор медицинских наук, профессор, М. Осадчук (1), доктор медицинских наук, профессор, А. Осадчук (2), доктор медицинских наук, профессор 1 -Первый МГМУ им. И.М. Сеченова 2 -Самарский государственный медицинский университет E-mail: osadchuk.mikhail@yandex.ru

На основе принципа доказательности представлены различные схемы эрадикации Helicobacter pylori (Hp), учитывающие характер антимикробной резистентности и степень эффективности элиминации Hp. Освещены перспективные направления совершенствования антимикробной терапии Hp-инфекции.
Ключевые слова: 
Helicobacter pylori
эрадикационная терапия
Для цитирования
Свистунов А., Осадчук М., Осадчук А. ПРИНЦИПЫ ВЫБОРА АНТИХЕЛИКОБАКТЕРНОЙ ТЕРАПИИ 1-й ЛИНИИ . Врач, 2015; (9): 7-11

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Барышникова Н.В., Денисова Е.В., Корниенко Е.А. и др. Эпидемиологическое исследование резистентности Helicobacter pylori к кларитромицину у жителей Санкт-Петербурга с язвенной болезнью // Экспер. и клин. гастроэнтерол. – 2009; 5: 73–6.
  2. Исаева Г.Ш. Резистентность Hp к антибактериальным препаратам и методы ее определения // Клин. микробиол. антимикроб. химиотер. – 2010; 12 (1): 57–66.
  3. Кудрявцева Л.В. Состояние антибиотикорезистентности Helicobacter pylori в России // Экспер. и клин. гастроэнтерол. – 2003; 3: 4–5.
  4. Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Клинико-молекулярные аспекты резистентности Helicobacter pylori к антибактериальным препаратам // Мед. совет. – 2013; 10: 11–5.
  5. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Актуальные возможности оптимизации антихеликобактерной терапии // Лечащий врач. – 2014; 4: 73–9.
  6. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Антибиотикорезистентность Helicobacter pylori: от клинического значения до молекулярных механизмов // Лечащий врач. – 2014; 2: 34–40.
  7. Маев И.В., Кучерявый Ю.А., Оганесян Т.С. и др. Какие схемы лечения инфекции Helicobacter pylori нужны нам сегодня? // Фарматека. – 2011; 11: 24–9.
  8. Самсонов А.А., Андреев Д.Н., Гречушников В.Б. и др. Резистентность Helicobacter pylori к компонентам эрадикационной терапии и пути ее преодоления // Фарматека. – 2015; 2: 26–30.
  9. Berning M., Krasz S., Miehlke S. Should quinolones come first in Helicobacter pylori therapy? // Ther. Adv. Gastroenterol. – 2011; 4: 103–14.
  10. Cardarolli S., Rolfo A., Todros T. Helicobacter pylori and pregnancy-related disoders // World J. Gastroenterol. – 2014; 20 (3): 654–64.
  11. Cetinkaya Z., Sezikli M., Güzelbulut F. et al. Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin // Helicobacter. – 2010; 15 (2): 143–7.
  12. Chey W., Wong B. American College of Gastroenterology guideline on the management of Helicobacter pylori infection // Am. J. Gastroenterol. – 2007; 102: 1808–25.
  13. Every A. Key host pathogen interactions for designing novel interventions against Helicobacter pylori // Trends Microbiol. – 2013; 21: 253–9.
  14. Federico A., Gravina A., Miranda A. et al. Eradication of Helicobacter pylori infection: Which regimen first? // World J. Gastroenterol. – 2014; 20 (3): 665–72.
  15. Federico A., Nardone G., Gravina A. et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection // Gastroenterology. – 2012; 143: 55–61.
  16. Fischbach L., Evans E. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori // Aliment. Pharmacol. Ther. – 2007; 26 (3): 343–57.
  17. Gatta L., Vakil N., Vaira D. et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequence therapy // BMG. – 2013; 7 (347): 4587.
  18. Gill S., O’Brien L., Einarson T. et al. The safety of proton pump inhibitors (PPI) in pregnancy: a meta-analysis // Am. J. Gastroenterol. – 2009; 104: 1541–5.
  19. Gisbert J., Calvel X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori // Clin. Exp. Gastroenterol. – 2012; 5: 23–34.
  20. Gisbert J., Perez-Aisa А., Castro-Femandez М. еt al. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin // Dig. Liver Dis. – 2010; 42 (287): 90.
  21. Graham D., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance // Gut. – 2010; 59 (8): 1143–53.
  22. Kim S., Lee S., Hyun J. et al. Comparative study of Helicobacter pylorieradication rates with 5-day quadruple «concominant» therapy and 7-day standard triple therapy // J. Clin. Gastroenterol. – 2013; 47: 21–4.
  23. Liang J., Li J., Han Y. et al. Helicobacter pylori eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a randomized, open-label, phase IV trial // Helicobacter. – 2012; 17 (6): 458–65.
  24. Liou J., Chang C., Chen M. et al. The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study // PLoS One. – 2015; 10 (5): 0124199.
  25. Mahadevan U. Gastrointestinal medications in pregnancy // Best Pract. Res. Clin. Gastroenterol. – 2007; 21: 849–77.
  26. Malfertheiner P., Bazzoli F., Delchier J. et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, methronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial // Lancet. – 2011; 377: 905–13.
  27. Malfertheiner P., Megraud F., O’Morain C. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report // Gut. – 2007; 56 (6): 772–81.
  28. Malfertheiner P., Megraud F., O'Morain C. et al. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report // Gut. – 2012; 61 (5): 646–64.
  29. Megraud F. Hp antibiotic resistance: prevalence, importance, and advances in testing // Gut. – 2004; 53: 1374–84.
  30. Megraud F. Antimicrobial Resistance and Approaches to Treatment. In: P. Sutton, H. Mitchell eds. Helicobacter pylori in the 21st Century / Wallingford, UK: CABI, 2010.
  31. Megraud F., Coenen S., Versporten A. et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption // Gut. – 2013; 62 (1): 34–42.
  32. Molina-Infante J., Romano M., Fernadez-Bermejo M. et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with rates of antibiotic resistance // Gastroenterology. – 2013; 145: 121–8.
  33. Nishizawa T., Nishizawa Y., Yahagi N. et al. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis // J. Gastroenterol. Hepatol. – 2014; 29 (4): 20–4.
  34. Perna F., Zullo A., Ricci C. et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance // Dig. Liver Dis. – 2007; 39 (11): 1001–5.
  35. Polat Z., Kadayaifci A., Kantarcioglu M. et al. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori // Eur. J. Intern. Med. – 2012; 23: 165–8.
  36. Riahizadeh S., Malekzadeh R., Agah S. et al. Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared or clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial // Helicobacter. – 2010; 15: 497–504.
  37. Romano M., Cuano A., Gravina A. et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomized trial // Gut. – 2010; 59: 1465–70.
  38. Sardarian H., Fakheri H., Hosseini V. et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial // Helicobacter. – 2013; 18 (2): 129–34.
  39. Smith S., O’Morain C., McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance // World J. Gastroenterol. – 2014; 20 (29): 9912–21.
  40. Sun Q., Liang X., Zheng Q. et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple for initial Helicobacter pylori eradication // Helicobacter. – 2010; 15 (3): 233–8.
  41. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment // Aliment. Pharmacol. Ther. – 2010; 32: 1069–79.
  42. Wang Z., Gao Q., Fang J. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium containing probiolic compound preparation in Helicobacter pylori eradication therapy // J. Clin. Gastroenterol. – 2013; 47: 25–32.
  43. Zhang Y., Xia H., Zhuang Z. et al. Review article: «true» re-infection of Helicobacter pylori after successful eradication-worldwide annual rates, risk factors and clinical implication // Aliment. Pharmacol. Ther. – 2009; 29: 145–60.